<DOC>
	<DOCNO>NCT00791011</DOCNO>
	<brief_summary>This multi-center , phase 1b study AMG 655 combination bortezomib vorinostat subject relapse refractory low grade lymphoma , mantle cell lymphoma , diffuse large cell lymphoma , Hodgkin 's disease . Part 1 open-label , dose-escalation phase ( 3+3 design ) determine safety , tolerability maximum tolerate dose AMG 655 combination bortezomib vorinostat . Subjects enrol one two arm base investigator selection ( either bortezomib + AMG 655 arm vorinostat + AMG 655 arm ) . Part 2 study dose expansion phase commence dose selection AMG 655 combination bortezomib Part 1 . In Part 2 , subject ( n = 20 ) mantle cell lymphoma give AMG 655 combination bortezomib . The dose AMG 655 use combination bortezomib base safety pharmacokinetic information obtain Part 1 well ongoing AMG 655 trial .</brief_summary>
	<brief_title>Phase 1b Lymphoma Study AMG 655 Combination With Bortezomib Vorinostat</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Part 1 : Subjects must pathologically confirm diagnosis lymphoma relapse refractory standard treatment curative therapy available . Lymphoma subtypes eligible enrollment include low grade lymphoma , mantle cell lymphoma , diffuse large cell lymphoma , Hodgkin 's disease . Part 2 : Subjects must relapse refractory mantle cell lymphoma least one objective measurable disease site ( ie , measurable least 2 perpendicular parameter ) . Subjects must least one prior antineoplastic therapy , maximum 3 . At least one therapy must include anthracycline . Subjects must document relapse progression follow last therapy ( ie , recent therapy give prior enrollment ) . An abnormal PET scan constitute evaluable disease , unless verify CT MRI scan ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic , renal , hepatic coagulation function A history malignancy , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease â‰¥ 5 year . A history allogeneic stemcell transplantation Primary central nervous system ( CNS ) tumor include primary CNS lymphoma Central nervous system involvement lymphoma Myocardial infarction within 6 month enrollment , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina , unstable cardiac arrhythmia require medication Vorinostat cohort : History significant GI surgery disease , would impair intestinal absorption Vorinostat cohort : Active peptic ulcer disease Prior exposure AMG 655 investigational TRAIL receptor agonist permit Prior treatment bortezomib vorinostat permit subject enrol bortezomib vorinostat cohort , respectively Major surgery within 28 day first dose AMG 655</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>AMG 655</keyword>
	<keyword>Trail receptor</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>SAHA</keyword>
	<keyword>Velcade</keyword>
</DOC>